Skip to main content

Table 3 Risk of cardiovascular events using the FPG, HbA1C, TyG index and concordance/discordance groups

From: Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1C in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular events: a cohort study from China

 

HR (95% CI)

Unadjusted

Model 1a

Model 2a

Model 3a

FPG tertiles

 Q1 (referent)

–

–

–

–

 Q2

0.99 (0.78–1.27)

1.00 (0.78–1.29)

1.00 (0.77–1.30)

0.98 (0.75–1.26)

 Q3

1.82 (1.46-2.26)†

1.81 (1.44-2.26)†

1.80 (1.43-2.27)†

1.76 (1.39-2.21)†

HbA1C tertiles

 Q1 (referent)

–

–

–

–

 Q2

1.75 (1.31–3.79)†

1.78 (1.34–2.36)†

1.79 (1.34–2.39)†

1.72 (1.29–2.28)†

 Q3

2.92 (2.24–3.79)†

2.85 (2.18–3.73)†

2.89 (2.20–3.80)†

2.70 (2.05–3.54)†

TyG tertiles

 Q1 (referent)

–

–

–

–

 Q2

1.42 (1.09–1.86)‡

1.46 (1.11–1.92)‡

1.46 (1.01–1.92)§

1.33 (1.01–1.76)§

 Q3

2.80 (2.21–3.55)†

2.81 (2.20–3.60)†

2.85 (2.22–3.67)†

2.36 (1.82–3.07)†

FPG/TyGa

 Low/low (referent)

–

–

–

–

 Low/High

2.10 (1.56–2.83)†

2.21 (1.63–2.99)†

2.22 (1.63–3.03)†

1.89 (1.38–2.59)†

 High/Low

1.41 (1.01–1.96)§

1.45 (1.03–2.04)§

1.43 (1.01–2.03)§

1.52 (1.07–2.15)§

 High/High

2.83 (2.22–3.60)†

2.81 (2.19–3.60)

2.83 (2.20–3.65)†

2.48 (1.92–3.21)†

HbA1C/TyGa

 Low/low (referent)

–

–

–

–

 Low/High

2.13 (1.50–3.01)†

2.20 (1.54–3.13)†

2.18 (1.52–3.12)†

1.92 (1.33–2.77)†

 High/Low

2.12 (1.52–2.95)†

2.12 (1.51–2.97)†

2.11 (1.50–2.97)†

2.28 (1.61–3.23)†

 High/High

3.99 (3.01–5.29)†

3.93 (2.94–5.26)†

3.99 (2.98–5.36)†

3.79 (2.78–5.17)†

  1. FPG fasting plasma glucose, HbA1C Glycosylated haemoglobin, TyG triglyceride glucose, HR hazard ratio, CI confidence interval
  2. †P<0.001
  3. ‡P<0.01
  4. §P<0.05
  5. aThe log-rank test and backward stepwise selection methods in a Cox proportional hazards regression model was performed; Model 1: adjusted for age, sex, BMI; Model 2: Model 1 + current smoker, hypertension, previous MI, previous stroke, previous PCI, previous CABG, ACS status; Model 3: Model 2 + non-HDL-C, lipid-lowering and antidiabetes medication use. Median HbA1C: 6.1%, median FBG: 6.19 mmol/L, median TyG:8.92